<DOC>
	<DOCNO>NCT00004154</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fenretinide , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether fenretinide effective placebo prevent recurrence bladder cancer surgery remove tumor . PURPOSE : This randomized phase III trial study fenretinide see well work compare placebo treat patient risk recurrent bladder cancer follow surgery remove tumor .</brief_summary>
	<brief_title>Fenretinide Treating Patients Who Have Undergone Surgery Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy , mechanism action , toxicity fenretinide patient risk recurrent superficial bladder cancer complete resection initial tumor . - Determine treatment effect modulate expression retinoid receptor , chromosomal abnormality ( numerical chromosomal abnormality DNA ploidy ) , apoptosis , autocrine motility factor receptor ( intermediate endpoint marker recurrent disease ) patient . OUTLINE : This randomize , multicenter study . Patients stratify accord lesion type ( multifocal v solitary ) . Patients randomize one two treatment arm . Patients receive either oral fenretinide placebo day 1-25 . Courses repeat every 28 day 1 year absence disease progression , unacceptable toxicity , development second primary cancer require therapy . Patients follow every 3 month 15 month . PROJECTED ACCRUAL : A total 178 patient ( 89 per arm ) accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solitary multifocal superficial ( stage Ta , grade 12 ) transitional cell carcinoma ( TCC ) bladder meet 1 follow criterion : Newly diagnose 4 week since resection Secondary tumor free ( include carcinoma situ ) 12 month intravesical therapy within 12 month OR Histologically proven Ta , T1 , Tis TCC bladder previously treat Bacillus CalmetteGuerin ( BCG ) . Must receive 6 week induction BCG follow evidence disease cystoscopy cytology treatment 3 weekly dos BCG . Visible tumor totally resect within 4 week prior study entry surgery , intravesical therapy , systemic therapy plan No prostatic , prostatic urethral , upper tract TCC involvement index tumor resection No metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod ( Eastern Cooperative Oncology Group ( ECOG ) ) 02 Life expectancy : At least 2 year Hematopoietic : white blood count ( WBC ) great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 11.0 g/dL Hepatic : serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) less 1.5 time upper limit normal ( ULN ) Renal : Creatinine le 2.0 mg/dL Other : Triglyceride level le 2.5 time ULN No concurrent malignancy except nonmelanomatous skin cancer No malignancy within past 5 year unless currently disease free , least 6 month since prior therapy , current plan active therapy , expect diseasefree survival least 2 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent systemic biologic therapy Chemotherapy : See Disease Characteristics No prior systemic cytotoxic chemotherapy bladder cancer At least 1 year since prior cytotoxic chemotherapy nonbladder cancer No concurrent systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy bladder No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 3 month since prior highdose vitamin A ( great 25,000 IU ) beta carotene ( least 30 mg/day ) At least 3 month since prior retinoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>